Symptoms improved with treatment changes in later stages of Parkinson’s
By
Kristen Fischer
Dec 20, 2023
A recent study showed that changing up therapies in the later stages of Parkinson’s disease improved motor symptoms and other subjective symptoms. As a result, doctors should consider advanced therapy...
Alzheimer’s drug donanemab finds late-stage trial success, safety concerns
By
Alicia Lasek
May 04, 2023
The experimental drug donanemab appears to halt the progression of Alzheimer’s disease and slow certain measures of clinical decline, new trial data show.
After receiving COVID-19 shots, many NY healthcare workers doubted boosters, study shows
By
Kristen Fischer
Apr 17, 2024
Healthcare workers at a New York health system likely aren’t exactly lining up to get the latest COVID-19 boosters. According to a survey of healthcare workers at HCP between 2021 and 2022, 17% were...
Palliative care screening in ICU may lead to better patient outcome
By
Donna Shryer
Apr 03, 2024
In the intensive care unit, every second counts when treating critically ill patients. But among the cutting-edge technologies, there is rarely any sort of defined process to swiftly identify patients...
Clinical briefs for Thursday, March 14
By
Kristen Fischer
Mar 14, 2024
6 in 10 Austrialians in care take antidepressants … Pneumococcal shot could do double duty to fight viral respiratory infections … Study: Rebounds occurred with both COVID-19 antivirals … Quest stops...
Survey: U.S. neurologists would prescribe Leqembi if fully approved
By
Alicia Lasek
Apr 12, 2023
A “healthy proportion” of surveyed neurologists have already begun prescribing the treatment, and nearly all said they planned to do so if traditional FDA approval is granted.
Pfizer asks FDA to approve omicron-specific booster shot
Aug 22, 2022
The drug company says that its new mRNA vaccine produces an immune response against the BA.4 and BA.5 omicron subvariants.
Benefits of Alzheimer’s drug Leqembi persist when treatment is halted, trial shows
By
Alicia Lasek
Apr 09, 2023
A relative slowing of cognitive decline continues for up to two years in patients who stop taking the recently authorized drug, clinical trial data reveal.
Program that diagnosed fractures virtually led to fewer ER visits for LTC residents: study
By
Alicia Lasek
May 14, 2023
A program that enabled virtual diagnosis and on-site fracture care kept 100% of participating LTC residents out of the emergency department and cut the need for clinic visits, a new study reveals.
Senators blast HHS’ restrictive coverage for Alzheimer’s drugs
By
Ron Rajecki
Mar 24, 2023
Health and Human Services Secretary Xavier Becerra came under fire Wednesday during a Senate Finance Committee meeting regarding the Centers for Medicare & Medicaid Services’ restrictive national...